1. Volume 90, Issue 3, Pages 696-704 (September 2016)
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors 
Matthew R. Weir, George L. Bakris, Coleman Gross, Martha R. Mayo, Dahlia Garza, Yuri Stasiv, Jinwei Yuan, Lance Berman, Gordon H. Williams 
Kidney International 
Volume 90, Issue 3, Pages (September 2016)
DOI: /j.kint
Copyright © 2016 International Society of Nephrology Terms and Conditions

2. Figure 1
Observed mean values of serum aldosterone and potassium over time during the initial treatment phase. The observed mean values were measured in a central laboratory. Missing central laboratory serum potassium values were imputed from local laboratory data.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

3. Figure 2
Effect of patiromer on observed mean values of systolic (a) and diastolic (b) blood pressure over time during the initial treatment phase.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions